Clinical trial
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute…
NCT00136903 · Mesoblast, Inc., Industry · Completed
Key facts
| NCT number | NCT00136903 |
|---|---|
| Title | Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) |
| Official title | A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation |
| Lead sponsor | Mesoblast, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Vs Host Disease |
| Intervention type | Drug |
| Interventions | Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone, Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil |
| Enrollment | 32 |
| Start date | Apr 27, 2005 |
| Primary completion | Jul 28, 2006 |
| Completion | Jul 14, 2008 |
| First posted | Aug 29, 2005 |
| Last update posted | Jan 31, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: